|Bid||39.07 x 4000|
|Ask||39.10 x 1000|
|Day's range||38.42 - 39.93|
|52-week range||34.37 - 46.47|
|Beta (3Y monthly)||0.59|
|PE ratio (TTM)||21.10|
|Earnings date||30 Apr 2019|
|Forward dividend & yield||1.44 (3.39%)|
|1y target est||44.36|
Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with moderate-to-severe osteoarthritis (OA) of the hip or knee. The tanezumab 5 mg treatment arm met two of the three co-primary efficacy endpoints, demonstrating a statistically significant improvement in pain and physical function compared to NSAIDs at the 16-week analysis, while patients’ overall assessment of their OA was not statistically different than NSAIDs. Patients who received tanezumab 2.5 mg did not experience a statistically significant improvement in pain, physical function or patients’ overall assessment of their OA at 16 weeks compared to NSAIDs.
Pfizer Inc. invites investors and the general public to listen to an audio webcast of the Annual Meeting of Shareholders at 9:00 a.m. Eastern Daylight Time on Thursday, April 25, 2019. To pre-register and access the live audio webcast, visit https://investors.pfizer.com/proxy and click on the “Meeting Webcast” button. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
Plunging healthcare stocks dragged Wall Street lower on Wednesday, offsetting a spate of upbeat corporate earnings and encouraging economic data from the United States and China. All three major U.S. stock indexes were down, but the S&P 500 slipped to more than a percent below its record high reached in September.
U.S. stocks headed lower on Wednesday, as a selloff in healthcare stocks extended for a second day, overshadowing a rally in chipmakers led by Qualcomm. Medical device maker Abbott Laboratories Inc fell 3.8%, despite quarterly results beating estimates. UnitedHealth Group Inc, Pfizer Inc and Merck & Co fell more than 2% and were the biggest drags on the broader S&P 500 index.
Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
Johnson & Johnson on Tuesday reported a first-quarter profit that exceeded Wall Street expectations on higher sales of its prescription medicines, including a double-digit increase for its psoriasis treatment Stelara, even as the company faces fierce competition for some of its other important drugs. Sales of Stelara, which also treats Crohn's disease, jumped about 32 percent to $1.41 billion, fueling a 4 percent rise for the pharmaceutical business, which accounts for more than half of the company's total revenue. Double-digit increases for cancer drugs Darzalex and Imbruvica also contributed to the earnings beat.
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Lorbrena’s approvalOn November 2, Pfizer (PFE) issued a press release announcing the FDA’s approval of Lorbrena, a third-generation TKI (tyrosine kinase
FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Xtandi’s growth trends According to Pfizer’s (PFE) fourth-quarter earnings conference call, Xtandi is a pillar of the company’s oncology business. In 2018, Pfizer
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Recent Ibrance approval On April 4, Pfizer (PFE) issued a press release announcing the FDA’s approval of its leading CDK4/6 (cyclin-dependent kinase 4/6) inhibitor
The U.S. FDA awarded Breakthrough Therapy Designation for this potential indication based on these Phase 2 data
Pfizer or AstraZeneca: Which Is a Better Pick in April?(Continued from Prior Part)Earnings guidance On its fourth-quarter earnings conference call, Pfizer (PFE) said that it expected its 2019 adjusted diluted EPS to be $2.82–$2.92, which doesn’t
Pfizer or AstraZeneca: Which Is a Better Pick in April?Stock price movementsOn April 11, Pfizer (PFE) closed at $42.27, 1.08% lower than its previous closing price, 22.99% higher than its 52-week low of $34.37, and 9.04% below its 52-week high of
The index traversed a lackluster trading week as investors looked toward first-quarter earnings numbers for direction.
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
RPMI Railpen, which benefits rail-industry retirees, also sold its large investment in Pfizer stock in the first quarter. It’s the U.K.’s sixth-largest pension fund by assets.